Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21119516 | 0.87 | PTGS1 (0.59) | PTGS1PTGS2HSD17B10GPBAR1TDP1 | |
| SCHEMBL12168915 | 0.82 | TDP1 (0.55) | PTGS2GPBAR1TDP1ALDH1A1MAPT | |
| SCHEMBL11234151 | 0.82 | PTGS1 (0.54) | PTGS1PTGS2HSD17B10GPBAR1ALDH1A1 | |
| SCHEMBL27936756 | 0.81 | CYP2C19 (0.60) | PTGS1PTGS2HSD17B10GPBAR1ALDH1A1 | |
| SCHEMBL5242041 | 0.80 | HSD17B10 (0.65) | PTGS1PTGS2HSD17B10GPBAR1ALDH1A1 | |
| SCHEMBL10394013 | 0.80 | PTGS1 (0.66) | PTGS1PTGS2HSD17B10GPBAR1TDP1 | |
| SCHEMBL10083918 | 0.80 | PTGS1 (0.66) | PTGS1PTGS2HSD17B10GPBAR1ALDH1A1 | |
| SCHEMBL5774888 | 0.79 | CYP2C19 (0.58) | PTGS1PTGS2HSD17B10GPBAR1ALDH1A1 | |
| SCHEMBL14258658 | 0.77 | PTGS1 (0.62) | PTGS1PTGS2HSD17B10GPBAR1ALDH1A1 | |
| SCHEMBL256699 | 0.76 | PTGS1 (0.59) | PTGS1PTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120141483-A1 | METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. | 2012-06-07 | — | — | US | disclosed |
| WO-2012028578-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER CROPSCIENCE AG (DE) | 2012-03-08 | — | — | WO | disclosed |
| US-20110152330-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | LOWE DEREK B | 2011-06-23 | — | — | US | disclosed |
| US-20110152331-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | LOWE DEREK B | 2011-06-23 | — | — | US | disclosed |
| US-20110065129-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | LOWE DEREK B | 2011-03-17 | — | — | US | disclosed |
| US-20090047687-A1 | Indane Acetic Acid Derivatives and Their Use as Pharmaceutical Agents, Intermediates, and Method of Preparation | LOWE DEREK B | 2009-02-19 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-7358386-B2 | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152331-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | INSR, ACACA, IAPP | PTGS1 807/4885PTGS2 899/4885HSD17B10 59/4885 |
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | PTGS1 1005/4885PTGS2 1588/4885HSD17B10 1632/4885 |
| US-20110152330-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | INSR, ACACA, IAPP | PTGS1 807/4885PTGS2 899/4885HSD17B10 59/4885 |
| US-20110065129-A1 | INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION | INSR, ACACA, IAPP | PTGS1 807/4885PTGS2 899/4885HSD17B10 59/4885 |
| US-20090047687-A1 | Indane Acetic Acid Derivatives and Their Use as Pharmaceutical Agents, Intermediates, and Method of Preparation | INSR, ACACA, IAPP | PTGS1 807/4885PTGS2 899/4885HSD17B10 59/4885 |
| US-20120141483-A1 | METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | APP, MAPT, TNF | PTGS1 482/4885PTGS2 353/4885HSD17B10 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.